Pain and discomfort are important symptoms in dermatology. The aim of this cross-sectional, multicentre study was to describe the prevalence of pain/discomfort and its associations in patients with several dermatological conditions across 13 European countries. The outcome was the prevalence of pain/discomfort according to a question of the EQ-5D questionnaire. Data collected from November 2011 to February 2013 were complete for 3,509 consecutive outpatients. Moderate or extreme pain/discomfort was reported by 55.5% of patients and 31.5% of controls with no skin conditions. The highest proportions were reported by patients with hidradenitis suppurativa (92.9%), leg ulcer (81.4%), prurigo (80%) and lichen planus (75.6%). Pain/discomfort was associated with older age, low educational level, clinical severity, flare on scalp or hands, itch, depression, anxiety, low quality of life, and thoughts of suicide. It is important to enquire specifically about pain/discomfort during clinical consultations and to address it when planning a patient’s care.

Key words: dermatology; discomfort; EQ-5D; pain.

Accepted Apr 2, 2020; Epub ahead of print Apr 6, 2020

Acta Derm Venereol 2020; 100: adv00120.

Corr: Jacek C. Szpeietowski, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Chalubinskiego 1, PL-50-368 Wroclaw, Poland. E-mail: jacek.szpeietowski@umed.wroc.pl

Pain and discomfort may be experienced by patients with dermatological conditions (1, 2). Pain has been defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” (3). This definition is still current, as it clearly defines pain as a subjective experience. Moreover, it links pain to both the sensory systems’ physiology and to the neurobiology of emotions, and it specifies that pain is associated with a specific adequate stimulus (4). Pain is an important symptom to be aware of clinically, since it is associated with profound effects on many aspects of quality of life (QoL) in many diseases (5).

The concept of discomfort is less well defined than pain, and has a slightly different meaning in different languages. In English “discomfort” may be defined as “slight pain” (Oxford English Dictionary), as “a painful feeling in part of your body when you have been hurt slightly or when you have been uncomfortable for a long time” (Collins English Dictionary), but also as the “feeling of being uncomfortable physically or mentally” (Cambridge English Dictionary). In a study that aimed to create a questionnaire on discomfort of body skin (6), 7 items were identified from consumers and confirmed by dermatologists’ experience: stinging, itching, tightness and warming, reported by the patient, and dryness, redness and desquamation, evaluated by the dermatologist.

Skin conditions are frequently responsible for unpleasant sensory symptoms, most obviously itch. However, pain, burning, and fatigue are also present in a large proportion of patients with skin conditions (2, 7, 8). In particular, pain is often reported by patients with psoriasis, atopic dermatitis (AD), and leg ulcers (8–11). However, only a few studies have investigated pain in other skin conditions (2, 7, 12, 13). Also, the presence of other unpleasant sensations that contribute to discomfort, such as stinging, tightness and warming, has been rarely investigated. This emphasizes the need to explore in more detail
the presence of unpleasant sensory symptoms in patients with a wide variety of skin conditions. To do this, we used the question from the EuroQoL-5D (EQ-5D) instrument that asks about the presence of pain/discomfort. The study was conducted in a large sample of patients with several dermatological conditions across 13 European countries.

MATERIALS AND METHODS

Study population

This report presents data from a large, multicentre, epidemiological study on the psychological burden of skin conditions. Methods have been described previously in detail (14). In brief, consecutive patients were recruited from dermatological outpatient clinics in 13 European countries from November 2011 to February 2013. Each centre had to collect data on 250 patients and 125 controls. Patients’ inclusion criteria were: age 18 years and over, being able to read and write the local language; having provided written informed consent. Patients were excluded if they had severe psychiatric conditions. The control group was recruited among employees at each study centre. The inclusion criteria were: age 18 years or more and no presence of skin condition, having provided written informed consent.

Collected data

Each patient was clinically examined by a dermatologist, who also collected information on comorbidities. The clinical severity of the skin condition was evaluated by the physician as either “mild”, “moderate” or “severe”. Patients were asked to complete a questionnaire with socio-demographic data and several questionnaires on the psychological burden of skin conditions. The clinical evaluation and the patient’s self-assessment were independent of each other.

Evaluation of pain or discomfort: the EQ-5D

The EQ-5D (15) questionnaire allows measurement of health-related QoL across all medical fields and across the general population. It has been used in skin conditions (16, 17), showing a good overall validity, especially for psoriasis and psoriatic arthritis (16). The EQ-5D includes a visual analogue scale (VAS) for self-rated health state from “0” (worst imaginable health state) to “100” (best imaginable health state), and 5 questions on mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each question has 3 possible answers. In this study we used data based on the question that asked subjects to rate “pain/discomfort” as either “I have no pain or discomfort” (score=0), or “I have moderate pain or discomfort” (score=1), or “I have extreme pain or discomfort” (score=2).

Depression and anxiety: the Hospital Anxiety and Depression Scale questionnaire

Symptoms of depression and/or anxiety in patients were evaluated using the Hospital Anxiety and Depression Scale (HADS) (18). It consists of 7 items assessing anxiety (HADS-A) and 7 assessing depression (HADS-D), each with 4 possible answers. For each dimension of anxiety and depression a person with a score of 0–7 is considered a normal case, 8–10 a borderline case, and 11–21 a case in need of further examination or treatment. In this paper we describe a subject with a score of 11–21 as a “clinical case”, and with a score of 8–10 as a “borderline case”. Although the EQ-5D asks about depression and/or anxiety, this is only an exploratory question that does not distinguish between the 2 conditions; hence the need to also use HADS as a screening tool to identify depression or anxiety separately.

Quality of life: the Dermatology Life Quality Index

Dermatology-specific health-related QoL was assessed using the Dermatology Life Quality Index (DLQI) (19). It consists of 10 questions, with possible answers from 0 (“not at all”) to 3 (“very much”). The total score is obtained by adding the score of each item. The following score band descriptors have been validated (20): total score 0–1: no effect at all on patient’s life; 2–5: small effect on patient’s life; 6–10: moderate effect on patient’s life; 11–20: very large effect on patient’s life; and 21–30: extremely large effect on patient’s life.

Suicidal ideation

To assess suicidal ideation due to the skin condition, the item “Have you ever thought of committing suicide because of your skin?” was included, with possible answers “yes” or “no”.

Sample size

As previously described (14), the statistical power was calculated on the basis of the prevalence of depression in the general population, estimated as 9%, and the expected prevalence in the dermatological population being higher (21). To identify a difference with a power of 0.80 and alpha=0.05 between a prevalence of depression of 9% in controls and 11% in cases, using a 1-sided test, 3,500 cases and 1,300 controls were needed (233 cases and 87 controls in each centre).

Statistical analysis

The answers to the “pain/discomfort” question of the EQ-5D were dichotomized into a variable “yes/no” by grouping the answers “I have moderate pain or discomfort” and “I have extreme pain or discomfort”. The frequency of pain/discomfort for the different dermatological conditions was calculated, and graphically represented by histograms. The group “psychodermatological diseases” included patients with factitial dermatitis, burning mouth, psychogenic itch, and trichotillomania. The association of pain with different variables was calculated: socio-demographic variables (sex, age, “living in the country of origin”, education, marital status, geographical region); clinical information (clinical severity of the skin condition, body site of the disease, presence of itch); presence of depression, presence of anxiety, suicidal thoughts, and DLQI score. The associations were analysed using odds ratios (ORs). Countries were grouped into Northern Europe (Denmark, Norway), Western Europe (Belgium, France, Germany, The Netherlands, UK), Eastern Europe (Hungary, Poland, Russia, Turkey), and Southern Europe (Italy, Spain). Logistic regression models were tested to estimate the degree of association of each variable of interest with pain/discomfort, while adjusting for all the other variables in the model. The dichotomous variable “pain/discomfort yes/no” was introduced in each model as the dependent variable. The independent variables were: sex, age, marital status, clinical severity, itch, depression, anxiety, and DLQI. Separate models were created for some diseases, selected on the basis of the number of patients (approximately 200 patients or more), i.e. psoriasis, eczema, non-melanoma skin cancer (NMSC), and acne. The diagnosis “eczema” included AD, eczema and hand eczema.

RESULTS

In total, 5,067 individuals agreed to participate; 3,651 patients and 1,416 controls. The participation rate was 79.9%. Of the initial 3,651 patients, 16 were excluded, 9 because they were too young and 6 because of missing data, leaving 3,635. Of the initial 1,416 controls, 57 were
subsequently excluded because, in the questionnaire specific for controls, they reported being treated for a skin disease, leaving 1,359. Information on pain/discomfort was available in 3,509 patients (96.5%). In the study population 43.6% were males, and the mean ± standard deviation age was 46.9 ± 17.2 years.

The disease was evaluated by the clinician as severe in 16.6% of patients, moderate in 45.3%, and mild in 38.1%. Clinical or borderline depression were present in 10.1% and 14.0% of patients, respectively (total prevalence of depression in cases 24.1%); clinical or borderline anxiety in 17.2% and 19.9%, respectively (total prevalence of anxiety in cases 37.1%). In patients, the presence of some pain/discomfort was reported by 49.7% of patients and extreme pain/discomfort by 5.8% (total prevalence 55.5%). In controls, these figures were 30.1% and 1.4%, respectively (total prevalence 31.5%). The prevalence observed in controls was quite high; however, it is consistent with that reported in other studies (22). Furthermore, while the overall prevalence rate ratio (PRR) of moderate or extreme pain/discomfort was 1.8, when considering only extreme pain, the PRR was 4.1. In the 4 geographical areas PRR of moderate or extreme pain/discomfort was quite homogeneous, varying from 1.5 in Western Europe to 2.0 in Southern Europe. The highest proportion of presence of pain/discomfort (Fig. 1) was reported by patients with hidradenitis suppurativa (92.9%), leg ulcer (81.4%), prurigo (80%), lichen planus (75.6%), and pruritus (75.0%). Patients reporting pain/discomfort were less frequently those with vitiligo (21.7%), naevi (23.6%), and acne (24.5%). The conditions with a higher prevalence of frequent pain/discomfort were prurigo (28.0%) and hyperhidrosis (27.3%). Pain/discomfort was associated with older age, low educational level, high clinical severity, flare on scalp or hands, and itch (Table I). It was less frequently reported by single patients or by patients with a flare on the face. As to mood disorders (Table II), the presence of borderline/clinical depression and anxiety, as well as thoughts of suicide, were strongly associated with pain/discomfort. The association between pain/discomfort and QoL increased substantially with increasing impairment in QoL, ranging from an OR of 2.18 for a small impairment of QoL up to 23.48 for a major impairment.

The multivariate models for single diseases (Table III) confirmed the strong association between pain/discomfort and low QoL in psoriasis, eczema, acne, and NMSC. Pain/discomfort was also significantly associated with the presence of anxiety in psoriasis, eczema, and acne. In psoriasis and acne, pain/discomfort was associated with itch. Age was positively associated with pain/discomfort in psoriasis and eczema.

**DISCUSSION**

In this study of a large number of dermatology outpatients, moderate or extreme pain/discomfort was reported by 55.5% of patients. The proportion was particularly high in patients with hidradenitis suppurativa, leg ulcer, prurigo, and lichen planus. Between 65% and 75% of patients with pruritus, blistering disorders, connective tissue disease, psychodermatological conditions, eczema, and pruritus experienced some or extreme pain/discomfort. These results are not directly comparable with those of previous studies, where only the dimension of pain was considered, or pain and discomfort were measured separately. For example, in a study of over 1,500 dermatological outpatients who used a specific questionnaire for neuropathic pain (7), skin pain was reported by 36.4% of patients. In another study (2), 23% of patients with skin diseases experienced pain evaluated with a VAS. Ljosaa et al. (9) reported a prevalence of 42% of skin pain and 37% of discomfort in patients with psoriasis. On the basis of these results we can speculate that approximately half of our patients reporting pain/discomfort actually had pain, and half had discomfort. This would be consistent with the results of the previous studies on the prevalence of pain in skin conditions.
In the current study, pain/discomfort was strongly associated with poor QoL, as also previously observed (1). We reported a significant association between pain/discomfort and both depression and anxiety. The association with anxiety was particularly strong, since it was significant even in the multivariate models when considering single conditions, such as psoriasis, eczema, and acne. It has been observed, in the musculoskeletal domain, that anxiety disorders, as well as other psychological symptoms, are associated with high levels of perceived pain (23, 24).

According to the biopsychosocial model (25), there might be a bidirectional relationship between anxiety/depres- sion and pain, including skin pain (26). Concerning the association with suicidal thoughts in the current study, the number of subjects was not large enough to know if suicidal thoughts were due to pain, especially as suicidal ideation was reported by a relatively small proportion of the participants. However, we have run a crude analysis for the association between pain and suicidal ideation, stratified by diagnosis. In general, we have observed that suicidal ideation was more frequent among patients reporting higher levels of pain/discomfort.

In the current study, pain/discomfort was more frequent in older patients. This could be due also to the presence of comorbidities. In fact, the EQ-5D question does not specify if pain/discomfort is due to a skin condition. This lack of specificity and presence of co-morbidities may also explain the reporting of pain/discomfort in conditions such as naevi and vitiligo.

Almost all patients with hidradenitis suppurativa reported moderate or extreme pain/discomfort. It is known that, among inflammatory dermatoses, hidradenitis suppurativa has the highest impact on QoL (27), presumably because of the frequent presence of symptoms, such as pain. Our results emphasize the importance of taking into account pain management when planning a treatment strategy for this condition (28).

Various studies with different samples and assessment methods have reported a range of percentages of patients with psoriasis experiencing pain. For example, in one study (8) 26% of psoriasis patients reported pain (up to 50% for psoriatic arthritis), but in that study a stringent definition of pain as experienced “often” or “all the time” was adopted. In the study by Ljosaa et al. (9), skin pain was reported by 42% of psoriasis patients, while in our study moderate or extreme pain/discomfort was reported by 66.3% of patients. In patients with psoriasis, pain was also strongly associated with the presence of itch. This is not surprising, since mechanisms that underlie the development of chronic itch and pain may overlap to a great extent (29).

Pain is present in patients with AD (30). Patients may scratch their skin, resulting in skin barrier disruption and painful erosions, but pain could also be partly related to neurogenic inflammation (31). In a previous study (11), pain and itch occurred together in 78% of patients with AD. It was observed that the presence of pain had an important impact on QoL, since it interfered with sleep, leisure activities, and daily living. In our study population, pain was strongly associated with older age and with anxiety.

---

### Table I. Prevalence of patients experiencing pain/discomfort in the study population according to demographic and clinical variables

| Variable                  | n (%)* | OR (95% CI) |
|---------------------------|--------|-------------|
| Sex                       |        |             |
| Male                      | 1,523  (53.9) | 1           |
| Female                    | 1,974  (56.6) | 1.12 (0.97–1.28) |
| Age                       |        |             |
| 18–40 years               | 1,314  (46.3) | 1           |
| 41–60 years               | 1,177  (58.2) | 1.61 (1.37–1.89) |
| >60 years                 | 956    (65.1) | 2.16 (1.30–2.58) |
| Origin                    |        |             |
| Home                      | 3,186  (55.0) | 1           |
| Foreign                   | 245    (59.6) | 1.21 (0.92–1.59) |
| Education                 |        |             |
| Primary                   | 1,431  (57.4) | 1           |
| Secondary                 | 1,039  (56.9) | 0.98 (0.83–1.15) |
| University                | 1,066  (51.2) | 0.78 (0.66–0.92) |
| Marital status            |        |             |
| Single                    | 837    (45.5) | 1           |
| Married                   | 1,851  (55.3) | 1.48 (1.25–1.74) |
| Divorced                  | 268    (65.7) | 2.29 (1.70–3.08) |
| Widow                     | 198    (76.8) | 3.96 (2.73–5.74) |
| Region                    |        |             |
| Eastern Europe            | 945    (53.8) | 1           |
| Northern Europe           | 736    (58.3) | 1.20 (0.99–1.46) |
| Western Europe            | 1,080  (55.0) | 1.05 (0.88–1.25) |
| Southern Europe           | 748    (55.9) | 1.09 (0.90–1.32) |
| Severity                  |        |             |
| Mild                      | 1,189  (46.3) | 1           |
| Moderate                  | 1,415  (59.6) | 2.25 (1.93–2.63) |
| Severe                    | 517    (66.9) | 3.09 (2.48–3.84) |
| Flare on face             |        |             |
| Yes                       | 1,272  (51.9) | 1           |
| No                        | 2,159  (57.9) | 1.28 (1.11–1.47) |
| Flare on scalp            |        |             |
| Yes                       | 910    (62.3) | 1.45 (1.23–1.69) |
| No                        | 2,527  (53.3) | 1           |
| Flare on hands            |        |             |
| Yes                       | 1,042  (67.1) | 1.98 (1.69–2.31) |
| No                        | 2,394  (50.8) | 1           |
| Itch                      |        |             |
| Yes                       | 1,576  (68.3) | 3.18 (2.76–3.67) |
| No                        | 1,869  (40.4) | 1           |

Data from 3,509 outpatients collected in 13 European countries from November 2011 to February 2013. *Totals may vary because of missing values. OR: odds ratio; CI: confidence interval. Bold numbers indicate statistically significant association.

---

### Table II. Prevalence of patients experiencing pain/discomfort in the study population according to psychological conditions and quality of life

| Variable                                  | n (%)* | OR (95% CI) |
|-------------------------------------------|--------|-------------|
| No depression                             | 2,636  (49.8) | 1           |
| Borderline depression                     | 486    (70.8) | 2.44 (1.97–3.03) |
| Clinical depression                       | 347    (77.8) | 3.54 (2.69–4.65) |
| No anxiety                                | 2,173  (47.1) | 1           |
| Borderline anxiety                        | 698    (55.9) | 2.17 (1.81–2.61) |
| Clinical anxiety                          | 590    (73.9) | 3.18 (2.59–3.92) |
| No thoughts of suicide                    | 3,249  (54.2) | 1           |
| Thoughts of suicide                       | 234    (73.9) | 2.40 (1.76–3.28) |
| Dermatology Life Quality Index            |        |             |
| No                                        | 969    (31.4) | 1           |
| Small                                     | 919    (49.9) | 2.18 (1.80–2.64) |
| Moderate                                  | 680    (65.9) | 4.22 (3.41–5.23) |
| Very large                                | 701    (76.6) | 7.16 (5.71–8.99) |
| Extreme                                   | 176    (91.5) | 23.48 (13.26–42.23) |

Data from 3,509 outpatients collected in 13 European countries from November 2011 to February 2013. *Totals may vary because of missing values. OR: odds ratio; CI: confidence interval. Bold numbers indicate statistically significant association.
In conclusion, pain/discomfort is a common symptom in dermatological patients and may be exacerbated by trauma or other unpleasant sensations. This may hinder comparisons with the results of other studies where pain/discomfort was chosen taking into account the translation issues. Moreover, the combination of the 2 terms has been used previously; for example, in a study on patients with psoriasis (40).

A strength of this study is that it includes data from a multicentre European initiative aimed at providing insight to the impact of skin diseases on QoL and psychological well-being. This involved the collection of a large amount of data using a single study design with standardized procedures and common research tools. There were no differences among regions in the prevalence of pain, which may indicate that it is the skin condition, and not factors specific to each country (health policy, climate, etc.), that influences the degree of pain/discomfort.

A possible issue of the use of the question about pain/discomfort concerns the translation of the term “discomfort” into different languages. The word “discomfort” does not have such a well-defined meaning as “pain”. The number of words that express a sensation, such as tingling, prickling and stinging, differs depending on the language used (37). High-standard validated translations and cross-cultural adaptations are crucial to ensure equivalence of meaning, as previously shown in a comparative study on pain (38). However, the original selection of the dimensions of the EQ-5D questionnaire was done on the basis of a survey of patients and the general population, and of a detailed review of other generic health measures (39). The dimension of pain/discomfort was chosen taking into account the translation issues. Moreover, the combination of the 2 terms has been used previously; for example, in a study on patients with psoriasis (40).

Table III. Logistic regression models for psoriasis, eczema, acne, and non-melanoma skin cancer (NMSC) patients, with pain/discomfort from the EuroQoL-5D (EQ-5D) questionnaire as the dependent variable

|                      | Psoriasis (n = 491) OR (95% CI) | Eczema (n = 410) OR (95% CI) | Acne (n = 197) OR (95% CI) | NMSC (n = 271) OR (95% CI) |
|----------------------|---------------------------------|------------------------------|---------------------------|----------------------------|
| **Sex**              |                                 |                              |                           |                            |
| Male                 | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| Female               | 1.05 (0.67–1.65)                | 1.39 (0.88–2.20)             | 0.83 (0.38–1.78)          | 0.85 (0.50–1.44)           |
| **Age, years**       |                                 |                              |                           |                            |
| 18–39                | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| 40–59                | 1.05 (0.63–1.73)                | 2.18 (1.24–3.84)             | 3.13 (1.35–8.28)          | 0.74 (0.20–2.70)           |
| >60                  | 3.08 (1.57–6.04)                | 3.27 (1.52–7.04)             | --                       | 1.57 (0.45–5.44)           |
| **Marital status**   |                                 |                              |                           |                            |
| Single               | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| Married              | 1.50 (0.88–2.56)                | 1.11 (0.64–1.92)             | 1.78 (0.73–4.32)          | 1.02 (0.33–3.13)           |
| Divorced (widow(er)) | 2.52 (1.10–5.79)                | 0.64 (0.28–1.44)             | 4.82 (0.15–154.49)        | 1.39 (0.40–4.86)           |
| **Severity**         |                                 |                              |                           |                            |
| Mild                 | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| Moderate             | 1.39 (0.84–2.30)                | 1.51 (0.92–2.47)             | 1.13 (0.49–2.61)          | 1.09 (0.61–1.95)           |
| Severe               | 1.54 (0.83–2.85)                | 1.26 (0.60–2.66)             | 1.72 (0.58–5.03)          | 0.99 (0.47–2.10)           |
| **Itch**             |                                 |                              |                           |                            |
| No                   | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| Yes                  | 2.80 (1.71–4.60)                | 1.06 (0.59–1.92)             | 2.19 (1.01–4.72)          | 1.66 (0.96–2.86)           |
| **Depression**       |                                 |                              |                           |                            |
| No                   | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| Yes                  | 1.51 (0.81–2.80)                | 1.07 (0.57–2.00)             | 1.70 (0.67–4.32)          | 1.84 (0.76–4.43)           |
| **Anxiety**          |                                 |                              |                           |                            |
| No                   | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| Yes                  | 1.70 (1.02–2.83)                | 2.36 (1.34–4.18)             | 3.04 (1.39–6.69)          | 1.12 (0.59–2.14)           |
| **DQLQ**             |                                 |                              |                           |                            |
| No                   | Ref.                            | Ref.                         | Ref.                      | Ref.                       |
| Small/moderate       | 2.01 (1.11–3.66)                | 3.38 (1.64–6.99)             | 3.38 (1.01–11.28)         | 2.35 (1.33–4.16)           |
| Very large/extreme   | 4.29 (2.19–8.42)                | 6.41 (2.87–14.32)            | 1.66 (0.39–7.08)          | 4.60 (0.76–27.81)          |

Each variable is adjusted for all the other variables. Data from 3,509 outpatients collected in 13 European countries from November 2011 to February 2013.

DQLQ: Dermatology Life Quality Index; EQ-5D: EuroQol-5D questionnaire; OR: odds ratio; CI: confidence interval. Bold numbers indicate statistically significant association.
ACKNOWLEDGEMENTS

Funding sources and conflicts of interest: FS and DA are partially supported by the "Progetto Ricerca Corrente RC 4.1.1" of the Italian Ministry of Health. Rome, Italy. FS acted as a consultant for AbbVie, Janssen, Eli Lilly, and Pierre Fabre; JS is a consultant and advisor for AbbVie, Celgene, Dignity Sciences, Leo Pharma, Novartis, Pierre-Fabre, Menlo Therapeutics, Sienna Pharmaceuticals and Sandoz, Investigator for AbbVie, Actelion, Amgen, GSK, Janssen, Merck, Novartis, Regereron, Takeda, Trevi, Speaker for AbbVie, Actavis, Astellas, Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly; AYF is joint copyright owner of the DLQI, Cardiff University and AYF receive royalties, AYF is a member of a Novartis advisory board.

REFERENCES

1. Ljosaa T, Mork C, Stubhaug A, Mouch T, Wahl AK. Skin pain and skin discomfort is associated with quality of life in patients with psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 29–35.
2. Verhoeven EWM, Kraaimaat FW, Van De Kerkhof PCM, Van Weel C, Duller P, Van Der Valk PGM, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156: 1346–1349.
3. Merskey H, Albe Fessard D, Bonica J, Carmon A, Dubner R, Kerr F, et al. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain (cited Oct 2) 1994; 51: 249–251.
4. Treede R-D. The International Association for the Study of Pain. Pain: definition of pain as valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain reports 2018; 3: e643.
5. McCarberg BH, Nicholson BD, Todd KH, Palmer T, Penles L. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther 2008; 15: 312–320.
6. Segot-Chicq E, Salah S, Jullien M, Portal N, Deschodt C, Gagnon D. Defining and validating a Body Skin Discomfort Index (BSDI). Int J Cosmet Sci 2018; 40: 488–493.
7. Misery L, Aromon M, Zikik A, Brian A, Martin L, Sigal M, et al. Chronic pain in patients with skin disorders. Acta Derm Venereol 2017; 97: 986–988.
8. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 1049–1054.
9. Lipsoa T, Rustoen T, Mork C, Stubhaug A, Miaskowski C, Paul S, et al. Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics. Acta Derm Venereol 2010; 90: 39–45.
10. Eusen M, Brenau E, Schoenaub P, Saliou P, Misery L. Neuropathic pain in patients with chronic leg ulcers. J Eur Acad Dermatol Venereol 2016; 30: 1603–1605.
11. Maarouf M, Kromenacker B, Capozza KL, Kempston D, Hendricks A, Tran K, et al. Pain and itch are dual burden in atopic dermatitis. Dermatitis 2018; 29: 278–281.
12. Mills KC, Kwatra SG, Feneran AN, Perez JJ, Mowles L. Pain and itch in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch Dermatol 2012; 148: 1422–1423.
13. Poulaloi A, Legoupil D, Schoenaub P, Haura M, Fonclare A, Poulaloi M, et al. Itch and pain characteristics in skin carcinomas. Acta Derm Venereol 2016; 96: 697–698.
14. Dalgard FJ, Gieler U, Tomas-Aragonés L, Lien L, Poot F, Jemece GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984–991.
15. EuroQol Group: EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
16. Yang Y, Brazier J, Longworth L. EQ-SD in skin conditions: an assessment of validity and responsiveness. Eur J Heal Econ 2015; 16: 927–939.
17. Baillea F, Kupfer J, Lien L, Gieler U, Finlay AY, Tomás-Aragonés L, et al. The burden of common skin diseases assessed with the EQ5DTM: a European multicentre study in 13 countries. Br J Dermatol 2017; 176: 1170–1178.
18. Myklebust A, Stordal E, Dahl AA. Hospital Anxiety and Depression (HADS) scale: factors structure, item analyses and internal consistency in a large population. Br J Psychiatry 2001; 179: 540–544.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
20. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659–664.
21. Hughes JE, Barralloumg BM, Hamblin LG, White JE. Psychiatric symptoms in dermatology patients. Br J Psychiatry 1983; 143: 51–54.
22. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016; 6: e010364.
23. Williams LJ, Pasco JA, Jacka FN, Dodd S, Berk M. Pain and the relationship with mood and anxiety disorders and psychological symptoms. J Psychosom Res 2012; 72: 452–456.
24. Barnett LA, Pritchard MG, Edwards JF, Afolabi EK, Jordan KP, Healey EL, et al. Relationship of anxiety with joint pain and its management: a population survey. Musculoskeletal Care 2018; 16: 353–362.
25. Novy DM, Aigner CJ. The biopsychosocial model in cancer pain. Curr Opin Support Palliat Care 2014; 8: 117–123.
26. Johnson S, Conroy C, Logan D. The biopsychosocial model of pain in the context of pediatric burn injuries. Eur J Pain 2019; 23: 421–430.
27. Matusiak Ł. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol 2018 May 9. [Epub ahead of print].
28. Jemec G. Quality of life considerations and pain management in hidradenitis suppurativa. Semin Cutan Med Surg 2017; 36: 75–78.
29. Schmelz M. Itch and pain differences and commonalities. Handb Exp Pharmacol 2015; 2227: 285–301.
30. Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol 2017; 119: 548–552.e3.
31. Brenau E, Garlantezec R, Talour K, Misery L. Itch characteristics in five dermatoses: non-atopic eczema, atopic dermatitis, urticaria, psoriasis and scabies. Acta Derm Venereol 2013; 93: 573–574.
32. Dika E, Vaccari S, Panti PA, Piraccini BM, Barisani A, Baralci C, et al. Pain evaluation in patients affected by cutaneous squamous cell carcinoma and actinic keratosis: an observational study. G Ital Dermatol Venereol 2017; 152: 413–417.
33. van Oosten EJ, Kuipers DM, Thissen MRM. Different pain sensations in photodynamic therapy of nodular basal cell carcinoma. Photodiagnostics Photodyn Ther 2006; 3: 61–68.
34. Poulaloi A, Legoupil D, Schoenlaub P, Haura M, Fonclare A-LD, Poulaloi M, et al. Itch and pain characteristics in skin carcinomas. Acta Derm Venereol 2016; 96: 697–698.
35. Lindeberg B, Bingefero K, Medling B, Berg M. Hand eczema and health-related quality of life; a comparison of EQ-5D and the Dermatology Life Quality Index (DLQI) in relation to the hand eczema extent score (HEES). Contact Dermatitis 2013; 69: 138–143.
36. Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol 2012; 92: 299–303.
37. Kim-Dufoir D-H, Poulaloi A, Misery L. The need for linguistically and culturally adapted standard questionnaires to assess itch: a preliminary study. Acta Derm Venereol 2017; 97: 991–992.
38. Sharma S, Pathak A, Jensen MP. Words that describe chronic musculoskeletal pain: implications for assessing pain quality across cultures. J Pain Res 2016; 9: 1057–1066.
39. Devlin NJ, Brooks R. EQ-SD and the EuroQol Group: past, present and future. Appl Health Econ Health Policy 2017; 15: 127–137.
40. Sobell JM, Foley P, Todd R, Mrowietz U, Girolomoni G, Goncalves J, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol 2016; 96: 514–520.